請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52944
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳基旺(Ji-Wang Chern) | |
dc.contributor.author | Tao Zhou | en |
dc.contributor.author | 周濤 | zh_TW |
dc.date.accessioned | 2021-06-15T16:35:18Z | - |
dc.date.available | 2020-09-24 | |
dc.date.copyright | 2015-09-24 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-12 | |
dc.identifier.citation | 1. Chayavichitsilp, P.; Buckwalter, J. V.; Krakowski, A. C.; Friedlander, S. F., Herpes simplex. Pediatrics in review / J. Pediatr. 2009, 30 (4), 119-29; quiz 130. 2. Whitley, R. J.; Roizman, B., Herpes simplex viruses: is a vaccine tenable? J. Clin. Invest. 2002, 110 (2), 145-151. 3. Whitley, R. J.; Kimberlin, D. W.; Roizman, B., Herpes Simplex Viruses. Clin. Infect. Dis. 1998, 26 (3), 541-553. 4. Wildy, P., Antigens of Herpes-Simplex Virus of Oral and Genital Origin. Cancer Res. 1973, 33 (6), 1465-1468. 5. Baron, S., Medical Microbiology, 4th edition. 1996; p 22. 6. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2013. Atlanta: U.S. Department of Health and Human Services; 2014. 7. Kaufman, H. E., Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine. Proc. Soc. Exp. Biol. Med. 1962, 109, 251-2. 8. Kaufman, H. E.; Heidelberger, C., Therapeutic Antiviral Action of 5-Trifluoromethyl-2'-deoxyuridine in Herpes Simplex Keratitis. Science 1964, 145 (3632), 585-586. 9. Littler, E.; Oberg, B., Achievements and challenges in antiviral drug discovery. Antiviral Chem. Chemother. 2005, 16 (3), 155-68. 10. Anderson, K. P.; Fox, M. C.; Brown-Driver, V.; Martin, M. J.; Azad, R. F., Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 1996, 40 (9), 2004-11. 11. Burrel, S.; Rouard, C.; Boutolleau, D., Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014, 370 (17), 1663-4. 12. Ohana, B.; Lipson, M.; Vered, N.; Srugo, I.; Ahdut, M.; Morag, A., Novel approach for specific detection of herpes simplex virus type 1 and 2 antibodies and immunoglobulin G and M antibodies. Clin. Diagn. Lab. Immunol. 2000, 7 (6), 904-8. 13. Mettenleiter, T. C., Herpesvirus assembly and egress. J. Virol. 2002, 76 (4), 1537-47. 14. Griffin, B. D.; Verweij, M. C.; Wiertz, E. J., Herpesviruses and immunity: the art of evasion. Vet. Microbiol. 2010, 143 (1), 89-100. 15. http://www.bio.davidson.edu/. 16. Schelhaas, M.; Jansen, M.; Haase, I.; Knebel-Morsdorf, D., Herpes simplex virus type 1 exhibits a tropism for basal entry in polarized epithelial cells. J Gen Virol. 2003, 84 (Pt 9), 2473-84. 17. Fatahzadeh, M.; Schwartz, R. A., Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J. Am. Acad. Dermatol. 2007, 57 (5), 737-63; quiz 764-6. 18. Gilden, D. H.; Mahalingam, R.; Cohrs, R. J.; Tyler, K. L., Herpesvirus infections of the nervous system. Nat. Clin. Pract. Neurol. 2007, 3 (2), 82-94. 19. Segal, A. L.; Katcher, A. H.; Brightman, V. J.; Miller, M. F., Recurrent herpes labialis, recurrent aphthous ulcers, and the menstrual cycle. J. Dent. Res. 1974, 53 (4), 797-803. 20. Freeman, D. J.; Sacks, S. L.; De Clercq, E.; Spruance, S. L., Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine cream. Antiviral Res. 1985, 5 (3), 169-77. 21. Pazin, G. J.; Ho, M.; Jannetta, P. J., Reactivation of herpes simplex virus after decompression of the trigeminal nerve root. J Infect Dis. 1978, 138 (3), 405-9. 22. Elion, G. B.; Furman, P. A.; Fyfe, J. A.; de Miranda, P.; Beauchamp, L.; Schaeffer, H. J., Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U. S. A. 1977, 74 (12), 5716-20. 23. De Clercq, E., Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemoth. 1993, 32 Suppl A, 121-32. 24. Miller, W. H.; Miller, R. L., Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J. Biol. Chem. 1980, 255 (15), 7204-7. 25. Miller, W. H.; Miller, R. L., Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem. Pharmacol. 1982, 31 (23), 3879-84. 26. Elion, G. B., Acyclovir: discovery, mechanism of action, and selectivity. J. Med. Virol. 1993, Suppl 1, 2-6. 27. Reardon, J. E.; Spector, T., Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J. Biol. Chem. 1989, 264 (13), 7405-11. 28. De Miranda, P.; Burnette, T. C., Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab. Dispos. 1994, 22 (1), 55-9. 29. Balimane, P. V.; Tamai, I.; Guo, A.; Nakanishi, T.; Kitada, H.; Leibach, F. H.; Tsuji, A.; Sinko, P. J., Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 1998, 250 (2), 246-51. 30. Piret, J.; Boivin, G., Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 2011, 55 (2), 459-72. 31. Earnshaw, D. L.; Bacon, T. H.; Darlison, S. J.; Edmonds, K.; Perkins, R. M.; Vere Hodge, R. A., Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 1992, 36 (12), 2747-57. 32. Vere Hodge, R. A.; Sutton, D.; Boyd, M. R.; Harnden, M. R.; Jarvest, R. L., Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. 1989, 33 (10), 1765-73. 33. Whitley, R. J.; Roizman, B., Herpes simplex virus infections. Lancet 2001, 357 (9267), 1513-8. 34. Krawczyk, A.; Arndt, M. A.; Grosse-Hovest, L.; Weichert, W.; Giebel, B.; Dittmer, U.; Hengel, H.; Jager, D.; Schneweis, K. E.; Eis-Hubinger, A. M.; Roggendorf, M.; Krauss, J., Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (17), 6760-5. 35. Anand, B. S.; Dey, S.; Mitra, A. K., Current prodrug strategies via membrane transporters/receptors. Expert Opin. Biol. Ther. 2002, 2 (6), 607-20. 36. Bacon, T. H.; Levin, M. J.; Leary, J. J.; Sarisky, R. T.; Sutton, D., Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 2003, 16 (1), 114-28. 37. Bush, L. M.; Talledo-Thais, K.; Casal-Fernandez, A.; Perez, M. T., Resistant Herpes Simplex Virus Infection and HIV: A Potential Diagnostic and Therapeutic Dilemma. Lab. Med. 2011, 42 (8), 452-457. 38. Patel, K.; Trivedi, S.; Luo, S.; Zhu, X.; Pal, D.; Kern, E. R.; Mitra, A. K., Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int. J. Pharm. 2005, 305 (1-2), 75-89. 39. Crowe, S. M.; Carlin, J. B.; Stewart, K. I.; Lucas, C. R.; Hoy, J. F., Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J. Acquired Immune Defic. Syndr. 1991, 4 (8), 770-6. 40. Drew, W. L., Cytomegalovirus infection in patients with AIDS. Clin. Infect. Dis. 1992, 14 (2), 608-15. 41. Jackson, J. B.; Erice, A.; Englund, J. A.; Edson, J. R.; Balfour, H. H., Jr., Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion. 1988, 28 (2), 187-9. 42. Culbertson, W. W., Infections of the retina in AIDS. Int Ophthalmol Clin. 1989, 29 (2), 108-18. 43. Burd, E. M.; Pulido, J. S.; Puro, D. G.; O'Brien, W. J., Replication of human cytomegalovirus in human retinal glial cells. Invest. Ophthalmol. Visual Sci. 1996, 37 (10), 1957-66. 44. Kenley, R. A.; Jackson, S. E.; Winterle, J. S.; Shunko, Y.; Visor, G. C., Water soluble complexes of the antiviral drugs, 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine and acyclovir: the role of hydrophobicity in complex formation. J. Pharm. Sci. 1986, 75 (7), 648-53. 45. Benjamin, E. J.; Firestone, B. A.; Bergstrom, R.; Fass, M.; Massey, I.; Tsina, I.; Lin, Y. Y., Selection of a derivative of the antiviral agent 9-[(1,3-dihydroxy-2-propoxy)-methyl]guanine (DHPG) with improved oral absorption. Pharm. Res. 1987, 4 (2), 120-5. 46. Arevalo, J. F.; Gonzalez, C.; Capparelli, E. V.; Kirsch, L. S.; Garcia, R. F.; Quiceno, J. I.; Connor, J. D.; Gambertoglio, J.; Bergeron-Lynn, G.; Freeman, W. R., Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J. Chemother. Infect. 1995, 172 (4), 951-6. 47. Cunha-Vaz, J. G., The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp. Eye Res. 2004, 78 (3), 715-21. 48. Morlet, N.; Young, S.; Naidoo, D.; Graham, G.; Coroneo, M. T., High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. , Br J Ophthalmol. 1996, 80 (3), 214-6. 49. Martin, D. F.; Ferris, F. L.; Parks, D. J.; Walton, R. C.; Mellow, S. D.; Gibbs, D.; Remaley, N. A.; Ashton, P.; Davis, M. D.; Chan, C. C.; Nussenblatt, R. B., Ganciclovir implant exchange. Timing, surgical procedure, and complications. Arch. Ophthalmol. 1997, 115 (11), 1389-94. 50. Rubio-Aliaga, I.; Daniel, H., Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol. Sci. 2002, 23 (9), 434-40. 51. Anand, B.; Nashed, Y.; Mitra, A., Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Curr. Eye Res. 2003, 26 (3-4), 151-63. 52. Dey, S.; Patel, J.; Anand, B. S.; Jain-Vakkalagadda, B.; Kaliki, P.; Pal, D.; Ganapathy, V.; Mitra, A. K., Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest. Ophthalmol. Visual Sci. 2003, 44 (7), 2909-18. 53. Bender, D. M.; Peterson, J. A.; McCarthy, J. R.; Gunaydin, H.; Takano, Y.; Houk, K. N., Cyclopropanecarboxylic acid esters as potential prodrugs with enhanced hydrolytic stability. Org. Lett. 2008, 10 (3), 509-511. 54. Hovgaard, L.; Brondsted, H.; Buur, A.; Bundgaard, H., Drug delivery studies in Caco-2 monolayers. Synthesis, hydrolysis, and transport of O-cyclopropane carboxylic acid ester prodrugs of various beta-blocking agents. Pharm. Res. 1995, 12 (3), 387-92. 55. Gao, H. W.; Mitra, A. K., Regioselective synthesis of various prodrugs of ganciclovir. Tetrahedron Lett 2000, 41 (8), 1131-1136. 56. Adams, L. A.; Aggarwal, V. K.; Bonnert, R. V.; Bressel, B.; Cox, R. J.; Shepherd, J.; de Vicente, J.; Walter, M.; Whittingham, W. G.; Winn, C. L., Diastereoselective synthesis of cyclopropane amino acids using diazo compounds generated in situ. J. Org. Chem. 2003, 68 (24), 9433-40. 57. Aggarwal, V. K.; Alonso, E.; Bae, I.; Hynd, G.; Lydon, K. M.; Palmer, M. J.; Patel, M.; Porcelloni, M.; Richardson, J.; Stenson, R. A.; Studley, J. R.; Vasse, J. L.; Winn, C. L., A new protocol for the in situ generation of aromatic, heteroaromatic, and unsaturated diazo compounds and its application in catalytic and asymmetric epoxidation of carbonyl compounds. Extensive studies to map out scope and limitations, and rationalization of diastereo- and enantioselectivities. J Am Chem Soc 2003, 125 (36), 10926-10940. 58. Neimert-Andersson, K.; Blomberg, E.; Somfai, P., Stereoselective synthesis of polyhydroxyl surfactants. Stereochemical influence on langmuir monolayers. J. Org. Chem. 2004, 69 (11), 3746-3752. 59. Landry, M. L.; Stanat, S.; Biron, K.; Brambilla, D.; Britt, W.; Jokela, J.; Chou, S.; Drew, W. L.; Erice, A.; Gilliam, B.; Lurain, N.; Manischewitz, J.; Miner, R.; Nokta, M.; Reichelderfer, P.; Spector, S.; Weinberg, A.; Yen-Lieberman, B.; Crumpacker, C., A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 2000, 44 (3), 688-92. 60. FDA Guidance for Industry, Analytical Procedures and Methods Validation: Chemistry, Manufacturing, and Controls Documentation, Draft Guidance, Food and Drug Administration. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52944 | - |
dc.description.abstract | 中文摘要 本論文旨在設計合成一系列噴昔洛韋之環丙烷氨基酸酯作為潛在抗疱疹病毒試劑並評估其生物活性。 最近本德爾團隊發現環丙烷酸酯能夠有效提高化合物在酸鹸環境的穩定性,這對於核苷酸優化設計來說無疑是好消息。結合之前的前體藥物設計理念,一系列噴昔洛韋之環丙烷氨基酸酯 (26a, 26b, 26c) 被設計出來用來作為潛在的抗病毒試劑,但是很遺憾,在生物活性測試實驗中該系列化合物對於疱疹病毒基本沒有活性。在對該系列化合物水解穩定性研究後發現,由於其水解時間過長,半衰期最高可達96天,不能夠釋放出足夠的母體藥物來對抗病毒,導致其基本沒有活性。為了進一步驗證該設計,我們又合成了更昔洛韋之環丙烷酰胺化合物 36,同樣的,由於其水解時間過長,半衰期達279天,其生物活性更低。我們的研究進一步說明了前體藥物的活性取決於母體藥物,以及取決於母體藥物與載體藥物所形成的鍵對酵素水解或者化學水解的活性。 我們的實驗研究表明以噴昔洛韋和更昔洛韋為母體藥物并結合環丙烷酸作為前體藥物的設計雖然能夠使得化合物水溶解性得到提高但該系列化合物沒有表現出抗病毒的活性。 | zh_TW |
dc.description.abstract | Abstract The aim of this dissertation is to design, synthesize and biologically evaluate penciclovir containing substituted cyclopropanecarboxylic acid esters as potential anti-HSV agents. Combining prodrug strategy and Bender’s research, cyclopropanecarboxylic acid ester prodrugs of penciclovir with enhanced hydrolytic stability was designed and expected to enhance permeation of penciclovir into the retinal and corneal tissues. But these compounds (26a, 26b, 26c) showed no activity against HSV-1 and HSV-2, a moderate activity against VZV. Even these compound possess a good water solubility, we found the half-life is too long, thus the parent drug penciclovir could not be released to inhibit the herpes. Furthermore, with an interest to modify the prodrug strategy, we turn to design the ganciclovir containing substituted cyclopropanecarboxylic amide 36. Even with a lot of efforts to synthesis this compound, it showed no activity against the herpes. And the analysis of the stability in phosphate buffer showed that it has a longer half-life of 279 days compared with penciclovir containing cyclopropanecarboxylic acid moiety probably because of the more stable feature of amide bond than the ester bond. These efforts and results suggest that the strategy of incorporating cyclopropanecarboxylic acid moiety to the penciclovir and ganciclovir were useful to improve the solubility but losing activity against herpes. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T16:35:18Z (GMT). No. of bitstreams: 1 ntu-104-R02423025-1.pdf: 4604123 bytes, checksum: a4e6d825c359a8a765d64e46d6608ca1 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Contents 中文摘要……………………………………………………………………………… i Abstract…………………………………………………………………………….... iii Content………………………………………………………………………………. v Lists of Schemes……………………………………………………………………. vi Lists of Figures………………………………………………………………….......vii Lists of Tables………………………………………………………………………. viii Lists of Abbreviations……………………………………………………………...... ix Chapter 1. Introduction……………………………………………………………… 1 1.1. Background of Herpes infection……………………………………..... 1 1.2. Mechanism of anti-herpes agents’ action……………………………… 3 1.3. Summary………………………………………………………………. 8 Chapter 2. Design and synthesis of target compounds………………………………10 2.1. Introduction…………………………………………………………....10 2.2. Rational Design………………………………………………………. 12 2.3. Synthetic Results……………………………………………………... 14 2.4. Biological activities and discussion………………………………….. 21 Chapter 3. Conclusion………………………..…………………………………… 23 Chapter 4. Experimental section…………………………………………………... 25 4.1. General information of synthesis…………………………………...... 25 4.2. General information of experimental method………………………... 25 4.3. Procedures and analytical data……………………………………...... 30 References…………………………………………………………………………... 57 Appendix………………………………………………………………………........ 65 | |
dc.language.iso | en | |
dc.title | 設計與合成噴昔洛韋之環丙烷酸酯作為潛在前體化合物並評估其抗疱疹病毒活性 | zh_TW |
dc.title | Design, Synthesis and Anti-HSV Activities of Penciclovir Containing Substituted Cyclopropanecarboxylic Acid Esters as Potential Prodrugs | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 顧記華(Jih-Hwa Guh),忻凌偉(Ling-Wei Hsin),梁碧惠(Pi-Hui Liang),王光昭(Kuang-Chao Wang) | |
dc.subject.keyword | 環丙烷酸酯,前體化合物,?疹病毒, | zh_TW |
dc.subject.keyword | Cyclopropanecarboxylic Acid Ester,HSV,Prodrug, | en |
dc.relation.page | 97 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-12 | |
dc.contributor.author-college | 藥學專業學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 4.5 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。